# Efficacy and Safety of Chemotherapy With XELOX (Oxaliplatin + Capecitabine) and Bevacizumab in Combination With Adebrelimab in First-line Treatment of Microsate

Source: https://onco.cc/trials/nct06282445/  
OnCo record `nct06282445` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of adebrelimab, fOLFOX (5-FU, leucovorin, oxaliplatin), capecitabine and bevacizumab (glioblastoma use) in colorectal cancer, run by The Fourth Affiliated Hospital of Zhejiang University School of Medicine, now recruiting.

## Summary

Efficacy and Safety of Chemotherapy With XELOX (Oxaliplatin + Capecitabine) and Bevacizumab in Combination With Adebrelimab in First-line Treatment of Microsatellite Stable (MSS) Initially Unresectable Metastatic Colorectal Cancer is a phase 2, interventional study registered as NCT06282445 by The Fourth Affiliated Hospital of Zhejiang University School of Medicine, with a registry enrolment figure of 36 participants, started 2024-03-01 and due to reach its primary completion in 2025-03-01. Interventions recorded: Adebrelimab; Oxaliplatin; Capecitabine; Bevacizumab. Conditions listed: Colorectal Cancer Metastatic. Primary outcome: Progression-free survival. Colorectal eligibility wording from the registry: "Metastatic colorectal cancer confirmed histologically and/or cytologically and initially unresectable". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT06282445
- Phase: 2
- Setting: Efficacy and Safety of Chemotherapy With XELOX (Oxaliplatin + Capecitabine) and Bevacizumab in Combination With Adebrelimab in First-line Treatment of Microsatellite Stable (MSS) Initially Unresectable Metastatic Colorectal Cancer: a Prospective, Multicenter, Single-arm Study
- Sponsor: The Fourth Affiliated Hospital of Zhejiang University School of Medicine
- Enrolled: 36

## Sources

- ClinicalTrials.gov NCT06282445: https://clinicaltrials.gov/study/NCT06282445

## Connected records

- cancers: [Colon cancer (adenocarcinoma of the colon)](https://onco.cc/cancers/colon-cancer/), [Rectal cancer](https://onco.cc/cancers/rectal-cancer/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/), [Platinum agents](https://onco.cc/technologies/platinum/)
- drugs: [Adebrelimab](https://onco.cc/drugs/adebrelimab/), [Bevacizumab (glioblastoma use)](https://onco.cc/drugs/bevacizumab-glioma/), [Capecitabine](https://onco.cc/drugs/capecitabine/), [FOLFOX (5-FU, leucovorin, oxaliplatin)](https://onco.cc/drugs/folfox/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06282445.json